My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener 🏛️ Insiders
✓ Last Updated: Nov 16, 2026 • Verified SEC EDGAR, 13F & Cboe Data for 2027 RQD Quant Engine v6.2 Live

Vertex Pharmaceuticals Incorporated (VRTX) — RQD Stock Rating Cockpit

$520.66 -2.94% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $519.15

Vertex Pharmaceuticals Incorporated (VRTX) earns a Roarable Rating of B (Buy) with 73/100 RQD Confidence. High-quality cash engine (86.2% gross margin, 20% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $132.01B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on VRTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is VRTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-22, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $520.66 (-2.94% 1D, market cap $132.01B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, VRTX ranks #31 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does VRTX compare to BMY and SNY in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRTX carries a Roarable B (73/100 RQD), trailing P/E of 34.6x, gross margin of 86.2%, and ROIC of 20.0%. By comparison, BMY (Bristol-Myers Squibb Company) holds a D+ grade (54/100 RQD, P/E 17.8x, ROIC 13.3%, cap $119.24B) and SNY (Sanofi ADS) posts a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $112.33B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for VRTX?
▼

Per VRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000875320), Vertex Pharmaceuticals Incorporated generated $12.00B in revenue (+8.9% YoY), $3.95B in net income, and $3.19B in free cash flow against $25.64B in total assets and $3.14B in total debt. Key quantitative strengths: Strong cash generator (86.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
🎯 VRTX TRADE EXECUTION LEVELS + TODAY'S TOP 3 TRADES EXACT ENTRY • HARD STOP-LOSS (SUP) • TARGET (RES) • WHY

Where to Enter $VRTX, Where to Set Your Hard Stop-Loss & Today's Top 3 High-Conviction Trades

🏆 RECENT ALERT WINNERS: $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
CURRENT TICKER SETUP • $VRTX R/R 2.9 : 1 • RQD 73/100 (B)
$VRTX
Spot $520.66
1. GET IN (ENTRY)
$517.54–$523.26
2. HARD STOP (SUP)
$497.23 (-4.5%)
3. GET OUT (T1/T2)
$561.27 / $589.39
STOP-LOSS FLOOR (SUP $497.23): Hard stop sits 4.5% below spot to cap downside below key institutional support. If $VRTX closes a daily candle below $497.23, step aside.
PROFIT TARGETS (RES $561.27 / $589.39): Scale out 50% at T1 (+7.8%) and trail stop to breakeven for T2 (+13.2%).
Want this $VRTX sheet + Today's Top 3 Trades emailed free? Paper Trade $VRTX →
⚡ TODAY'S TOP 3 SUGGESTED TRADES OF THE DAY (100% FREE CHEAT SHEET) Trade #1 Unlocked • Enter Email Below to Unblur #2 & #3 + Get $VRTX Sheet
#1 • $ANET R/R 2.6 : 1
Arista Networks Inc.
IN
$164.14
STOP
$154.80
OUT
$178.00
#2 • 🔒 LOCKED R/R 2.6 : 1
AI Liquid-Cooling Leader
Target: +8.81% to +15.06% | Stop: -5.73%
#3 • 🔒 LOCKED R/R 2.3 : 1
Cash-Flow Buyback Machine
Target: +6.22% to +10.48% | Stop: -4.52%
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $519.15 (-0.29%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 26.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 73/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.1% avg 90D alpha vs SPY • 69.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510073
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B · Rk B
Cash (17)Whales (11)SEC (16)Macro (14)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+6.7% Base Target
$656 Bull$556 Base$427 Bear
📬 FREE VRTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VRTX)Realized 20D OHLCV Swing Band: ±2.7%
Deterministic 5-Pillar Attribution (73/100 Composite)
🔍 WHY VRTX SCORES 73/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 26.6% FCF Margin ($3.19B FCF) & 86.2% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (22% of score)

Altman Z-Score 13.86 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning11/20 pts (-9 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-9 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
81
Grade A-$542.93+0.9% Next Q
Q2 (-2Q)
78
Grade A-$547.89-1.7% Next Q
Q3 (-1Q)
76
Grade B+$538.60-3.3% Next Q
Current
73
Grade B$520.66+7.1% Hist 90D α
Trajectory: A- (81) → B (73)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VRTX Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 73/100 (B) score, VRTX faces multiple-compression risk if 34.6x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 83.7% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($526.01) or 200D SMA ($486.87) invalidates the momentum regime and cuts Target Base ($555.80) toward Bear Floor ($426.94).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VRTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “VRTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
RSI-14 MOMENTUMNEUTRAL RANGE
39.730 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
13.86>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
8 / 99-Pt Accounting
52-WEEK LASER RANGE72% OF RANGE
L: $412$520.66H: $564
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (86.2% gross margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20
2. Big Money & Insiders● NEUTRAL
Are whales & executives buying or selling?

Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.

Factor Grade: CRQD 26 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 30 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bullish on VRTX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (85)

20.0% ROIC with 86.2% gross margin and 2.33% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (80)

Altman-Z 13.86 and Piotroski 8/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (67)

26/40 institutional & smart-money positioning score with 14/20 macro alignment.

Bull Case: Why Buyers Like VRTX
  • ✓Strong cash generator (86.2% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VRTX Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
VRTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +19.44%🛡️ HOLDING TREND SUPPORT
2026-11-22O $536.5H $536.5L $520.7C $520.7VOL 1.18M
$573.9$532.2$490.5$448.8$407.1RES $565.6SUP $507.3$520.72026-05-262026-07-132026-08-272026-10-132026-11-22
🏛️ GURU-GRADE VALUATION & FORENSIC ACCOUNTING ENGINE WIDE ECONOMIC MOAT (ROIC 20.0% vs WACC 8.3%)

VRTX Intrinsic Fair Value Line, Peter Lynch Corridor, Forensic Trio & Warning Signs

1-SECOND VISUAL VALUATION ANCHOR (COMPOSITE DCF + PETER LYNCH + GRAHAM)
Fair Value: $357.70 vs Spot $520.66
MODESTLY OVERVALUED (-45.6%)
Undervalued Zone (< $304) Fair Value Corridor ($304–$411) Overvalued (> $411)
$521
⚡ INTERACTIVE 10-YEAR DCF SANDBOX

Test Your Own VRTX Growth & WACC Assumptions

YOUR DCF TARGET
$466.29
5-Yr Annual FCF Growth Rate: 13.2%
Discount Rate (WACC Hurdle): 8.3%
Year-10 Terminal FCF Multiple: 16.0x
Margin of Safety: -45.6% vs $520.66 Full DCF Table →
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VRTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
26.7%/yr Implied 5Y Growth

vs. +8.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on VRTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VRTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for VRTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VRTX)

Health Care Rank #31 of 1015 ⚔️ BMY vs VRTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VRTX vs. BMY, SNY, PFE, NVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Vertex Pharmaceuticals Incorporated (VRTX) ranks #31 by composite RQD confidence (73/100, grade B) and #15 by equity capitalization ($132.01B). Within this direct 5-issuer industry benchmark cohort, BMY leads on earnings valuation at 17.8x trailing P/E, while VRTX leads on capital efficiency and profitability with 20.0% ROIC and 86.2% gross margin. VRTX currently leads its immediate peer cohort in composite quantitative strength at 73/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
VRTX ACTIVE
Vertex Pharmaceuticals Incorporated
B 73/100 34.6x 86.2% 20.0% -2.94% $132.01B Benchmark Subject
BMY
Bristol-Myers Squibb Company
D+ 54/100 17.8x 71.1% 13.3% -2.06% $119.24B /bmy-vs-vrtx →
SNY
Sanofi ADS
C 62/100 32.8x — 9.9% -2.25% $112.33B /sny-vs-vrtx →
PFE
Pfizer Inc.
C- 61/100 22.0x 74.3% 5.1% -1.75% $157.14B /pfe-vs-vrtx →
NVO
Novo Nordisk A/S
D+ 55/100 32.8x — 9.9% -1.37% $172.20B /nvo-vs-vrtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000875320 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Vertex Pharmaceuticals Incorporated (VRTX) reported GAAP revenue of $12.00B (+8.9% vs. FY2024 revenue of $11.02B , and +21.6% cumulative change since FY2023) , GAAP net income of $3.95B, operating cash flow of $3.63B, and free cash flow of $3.19B (+504.1% YoY). On the balance sheet, VRTX closed FY2025 with $25.64B in total assets against $3.14B in total debt (Altman Z-Score: 13.86, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $12.00B $3.95B $3.63B $3.19B $25.64B $3.14B
FY2024 (FY) 2024-12-31 $11.02B -$535.6M -$492.6M -$790.3M $22.53B $2.76B
FY2023 (FY) 2023-12-31 $9.87B $3.62B $3.54B $3.09B $75.28B $17.62B

3. VRTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VRTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-22, Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 73/100 at a spot price of $520.66 (-2.94% 1D, market cap $132.01B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 11/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 15/20. Across 1015 tracked Health Care issuers, VRTX ranks #31 in composite RQD confidence.

How does VRTX compare to BMY and SNY in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VRTX carries a Roarable B (73/100 RQD), trailing P/E of 34.6x, gross margin of 86.2%, and ROIC of 20.0%. By comparison, BMY (Bristol-Myers Squibb Company) holds a D+ grade (54/100 RQD, P/E 17.8x, ROIC 13.3%, cap $119.24B) and SNY (Sanofi ADS) posts a C grade (62/100 RQD, P/E 32.8x, ROIC 9.9%, cap $112.33B). Among the 5-stock peer group, BMY leads on earnings multiple (17.8x) while VRTX leads on capital efficiency (20.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VRTX?

Per VRTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000875320), Vertex Pharmaceuticals Incorporated generated $12.00B in revenue (+8.9% YoY), $3.95B in net income, and $3.19B in free cash flow against $25.64B in total assets and $3.14B in total debt. Key quantitative strengths: Strong cash generator (86.2% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VRTX trading relative to its 50-day, 200-day, and 52-week technical levels?

VRTX last traded at $520.66 (-2.94% on volume of 1,177,432 shares), positioning the stock -1.02% below its 50-day simple moving average ($526.01) and +6.94% above its 200-day simple moving average ($486.87). Across its 52-week range of $412.27 to $563.80, VRTX sits at the 71.5% percentile with a 14-day RSI of 39.7 (NEUTRAL RANGE) and an implied next-earnings move of ±2.7% ($506.60 to $534.72).

ROARABLE RATING BRIEF • RQD 73/100 (B) ✓ SEC XBRL & RQD VERIFIED

VRTX — Vertex Pharmaceuticals Incorporated: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Vertex Pharmaceuticals Incorporated (VRTX) earns a live Roarable RQD composite score of 73/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $520.66 (-2.94% 1D, market capitalization $132.01B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 20.0%, gross margin of 86.2%, operating margin of 34.8%, and free cash flow yield of 2.33%.
  • Whale 13F & Options Flow (11/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (16/20): Incorporates a 1.02x equity beta, Altman Z-Score of 13.86, Piotroski F-Score of 8/9, and Debt/Equity of 0.16x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Vertex Pharmaceuticals Incorporated (VRTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. It is a publicly traded US company with a market capitalization of $136.9B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Vertex Pharmaceuticals Incorporated (VRTX) reported $12.00B in annual revenue (up from $11.02B in FY2024, +8.9% YoY) and $3.95B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($9.87B revenue, $3.62B net income) through FY2025, VRTX scaled operating cash flow to $3.63B and free cash flow to $3.19B, backed by $25.64B in total assets against $3.14B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 73/100): Strong cash generator (86.2% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 11/20, sustained execution supports upside toward the upper end of the $412.27 – $563.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 34.6x trailing P/E and 29.6x EV/EBITDA against 34.8% operating margins and a 1.02x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be identified from the source data.

  • Key Question #1: Can VRTX sustain or expand its 34.8% operating margin and 20.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $12.00B and free cash flow of $3.19B, how will capital allocation balance growth reinvestment against $3.14B in total debt?
  • Key Question #3: How sensitive is VRTX's 32.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.02x)?

VRTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Vertex Pharmaceuticals Incorporated (VRTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to VRTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

VRTX Bull vs. Bear Conversation Board — What's Your Call at $520.66?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON VRTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on VRTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $665.07 (+19.0%)
📌 Pinned Debate

ROIC of 20% with a 32.9% net margin and Piotroski F 8/9 show a high-quality, cash-generative franchise.

Don't sleep on VRTX's setup in Health Care. ROIC of 20% with a 32.9% net margin and Piotroski F 8/9 show a high-quality, cash-generative franchise.. Beta of 1.02 means it moves fast when momentum turns, and the 5-pillar RQD gauge (83/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — VRTX's 16/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $435.93 (-22.0%)
Spot @ $558.88

A P/E TTM of 34.6 against a 2.33% FCF yield leaves a thin valuation margin of safety.

Sitting on the sidelines or leaning short VRTX above $558.88. A P/E TTM of 34.6 against a 2.33% FCF yield leaves a thin valuation margin of safety.. Until Fundamental Cash Engine (17/20) and FCF yield (2.33%) inflect higher, upside is capped near $563.80.

🎯 DAILY PRE-BELL WATCHLIST • ENTRY, HARD STOP & TARGET EDUCATIONAL LEVELS ONLY • EVERY TRADE CARRIES RISK

3 Stocks on Our Radar Today — Entry, Hard Stop & Why

📊 Recent Paper Examples (Not Typical Real-Money Results): $XYZ +15.6% (2d) $PLTR +13.7% (4d) $VRT +8.4% (2d)
TRADE #1 OF THE DAY R/R 2.6 : 1 • RQD 88 (A+)
$ANET Arista Networks Inc.
LONG (BUY SETUP)
1. Get In (Entry)
$164.14
2. Hard Stop
$154.80 (-5.7%)
3. Get Out (T1/T2)
$178.00 / $188.50
Entry Rule: Buy between $162.50 – $165.00 (or on 15-min candle reclaim above $165.40)
Stop Logic: Hard stop at $154.80 sits beneath the 50-day institutional demand shelf and October accumulation base—capping downside at -5.69% while targeting $178.00 to $188.50 (+14.84%).
4. Why Now: Microsoft (+6.68%) and Amazon (+6.12%) just surged while confirming $320B+ in data-center CapEx, yet passive ETF rebalancing pushed ANET down -2.79% to $164.14. Arista owns the 64.1% gross-margin 800G/1.6T back-end AI Ethernet switching monopoly that cashes those exact hyperscaler checks.
Horizon: 4–10 Trading Days (Supply-Chain Contagion Mean-Reversion Swing) Trade $ANET in $100K Arena →
TRADE #2 OF THE DAY R/R 2.6 : 1 • RQD 86 (A)
🔒 Setup #2: 130kW Direct-to-Chip Liquid Cooling & CDU Thermal Monopoly Pullback
LONG (BUY SETUP)
• Target Upside: +8.8% (T1) to +15.1% (T2)
• Max Downside Stop: -5.7% Hard Floor (2.6 : 1 R/R)
Order book sold out through 2027 on key VWAP support. Enter your email below for the ticker, buy trigger, and stop.
TRADE #3 OF THE DAY R/R 2.3 : 1 • RQD 85 (A)
🔒 Setup #3: 13.27x Forward P/E Money-Center Infrastructure Debt Underwriting Breakout
LONG (BUY SETUP)
• Target Upside: +6.2% (T1) to +10.5% (T2)
• Max Downside Stop: -4.5% Hard Floor (2.3 : 1 R/R)
Big-bank infrastructure lender breaking out with a -4.5% stop floor. Enter your email below for the entry zone and target.
Horizon: 5–12 Trading Days (Relative-Strength Financials Breakout)
⚡ See Setups #2 & #3 Right Now + Tomorrow's 3 Setups at 8:00 AM ET
Free impersonal market research. Educational levels only — past setups include losing stops and carry real risk of loss.
2. Guru Strategy Screeners, Formula Hub & Head-to-Head Battles
LIVE TAPE